Stalicla (Series C)
Funding Details
Awarder
Inbox
Date Award
July 2, 2025
Vertical
biotech
Funding URL
View Funding Page
Funding Amount
$2,000,000
Company Info
Traction
Stalicla is preparing to initiate Phase 2 trials for its leading NDD asset, STP1, along with a second asset, both targeting specific subpopulations within autism. Additionally, STP7 (Mavoglurant) is progressing towards Phase 3 trials.
Market
neurodevelopmental disorders
Location
Geneva, Switzerland
Company Description

Stalicla is a clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders (NND). The company has established a clinically validated neuro precision development platform that effectively identifies stratified patient subgroups, enabling the advancement of personalized treatment options.

Links
Website
Back to HomeBack to biotech DealsView Funding Announcement